Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Cases
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for N-acetylcysteine  COVID-19 treatment studies for N-acetylcys..  C19 studies: N-acetylcys..  N-acetylcys..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 N-acetylcysteine studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 25% 8 817 Improvement, Studies, Patients Relative Risk Mortality 67% 4 355 Ventilation 8% 3 273 ICU admission 14% 3 273 Hospitalization 16% 6 735 Recovery 58% 3 442 Cases 26% 1 0 RCTs 15% 4 578 RCT mortality 11% 2 227 Peer-reviewed 33% 7 817 Prophylaxis 26% 1 0 Early 21% 2 416 Late 52% 5 401 N-acetylcysteine for COVID-19 c19early.com/na Jan 16, 2022 Favors N-acetylcysteine Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1 Improvement, RR [CI] Treatment Control Ignatova 20% 0.80 [0.64-1.00] hosp. time 56 (n) 55 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.043 Early treatment 21% 0.79 [0.63-0.99] 0/285 1/131 21% improvement de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 Improvement, RR [CI] Treatment Control Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Assimakopoulos 97% 0.03 [0.00-0.30] death 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] death 1/24 3/22 Tau​2 = 0.55, I​2 = 81.8%, p = 0.071 Late treatment 52% 0.48 [0.22-1.06] 24/204 38/197 52% improvement Huh 26% 0.74 [0.68-0.80] cases population-based cohort Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Prophylaxis 26% 0.74 [0.68-0.80] 26% improvement All studies 25% 0.75 [0.61-0.91] 24/489 39/328 25% improvement 8 N-acetylcysteine COVID-19 studies c19early.com/na Jan 16, 2022 Tau​2 = 0.03, I​2 = 73.5%, p = 0.0041 Effect extraction pre-specified 1 CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ de Alencar (DB RCT) -3% 1.03 [0.41-2.27] 9/67 9/68 Improvement, RR [CI] Treatment Control Taher (DB RCT) 18% 0.82 [0.43-1.58] 12/47 14/45 Assimakopoulos 97% 0.03 [0.00-0.30] 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] 1/24 3/22 Tau​2 = 1.63, I​2 = 84.8%, p = 0.12 Late treatment 67% 0.33 [0.08-1.36] 24/180 38/175 67% improvement All studies 67% 0.33 [0.08-1.36] 24/180 38/175 67% improvement 4 N-acetylcysteine COVID-19 mortality results c19early.com/na Jan 16, 2022 Tau​2 = 1.63, I​2 = 84.8%, p = 0.12 Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ de Alencar (DB RCT) -16% 1.16 [0.59-2.01] 16/67 14/68 Improvement, RR [CI] Treatment Control Taher (DB RCT) 14% 0.86 [0.53-1.40] 18/47 20/45 Avdeev 77% 0.23 [0.03-1.90] 1/24 4/22 Tau​2 = 0.02, I​2 = 10.9%, p = 0.7 Late treatment 8% 0.92 [0.60-1.40] 35/138 38/135 8% improvement All studies 8% 0.92 [0.60-1.40] 35/138 38/135 8% improvement 3 N-acetylcysteine COVID-19 mechanical ventilation results c19early.com/na Jan 16, 2022 Tau​2 = 0.02, I​2 = 10.9%, p = 0.7 Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ de Alencar (DB RCT) 9% 0.91 [0.59-1.28] 29/67 32/68 Improvement, RR [CI] Treatment Control Taher (DB RCT) 20% 0.80 [0.44-1.47] 47 (n) 45 (n) Avdeev 77% 0.23 [0.03-1.90] 1/24 4/22 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment 14% 0.86 [0.63-1.17] 30/138 36/135 14% improvement All studies 14% 0.86 [0.63-1.17] 30/138 36/135 14% improvement 3 N-acetylcysteine COVID-19 ICU results c19early.com/na Jan 16, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1 Improvement, RR [CI] Treatment Control Ignatova 20% 0.80 [0.64-1.00] hosp. time 56 (n) 55 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.043 Early treatment 21% 0.79 [0.63-0.99] 0/285 1/131 21% improvement de Alencar (DB RCT) -10% 1.10 [0.37-3.23] hosp. time 67 (n) 68 (n) Improvement, RR [CI] Treatment Control Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Taher (DB RCT) 33% 0.67 [0.31-1.45] hosp. time 47 (n) 45 (n) Avdeev 15% 0.85 [0.75-0.96] hosp. time 24 (n) 22 (n) Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 15% 0.85 [0.78-0.91] 0/162 0/157 15% improvement All studies 16% 0.84 [0.78-0.90] 0/447 1/288 16% improvement 6 N-acetylcysteine COVID-19 hospitalization results c19early.com/na Jan 16, 2022 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 1 CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.33 Early treatment 80% 0.20 [0.01-4.85] 0/229 1/76 80% improvement de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 Improvement, RR [CI] Treatment Control Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Assimakopoulos 97% 0.03 [0.00-0.30] death 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] death 1/24 3/22 Tau​2 = 1.63, I​2 = 84.8%, p = 0.12 Late treatment 67% 0.33 [0.08-1.36] 24/180 38/175 67% improvement All studies 68% 0.32 [0.09-1.15] 24/409 39/251 68% improvement 5 N-acetylcysteine COVID-19 serious outcomes c19early.com/na Jan 16, 2022 Tau​2 = 1.50, I​2 = 80.1%, p = 0.08 Effect extraction pre-specified 1 CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 83% 0.17 [0.13-0.24] no recov. 229 (n) 75 (n) CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Early treatment 83% 0.17 [0.13-0.24] 0/229 0/75 83% improvement Gaynitdinova (RCT) 51% 0.49 [0.32-0.75] Ct imp. 24 (n) 22 (n) Improvement, RR [CI] Treatment Control Taher (DB RCT) 15% 0.85 [0.60-1.22] no recov. 25/47 28/45 Tau​2 = 0.11, I​2 = 74.3%, p = 0.13 Late treatment 34% 0.66 [0.38-1.13] 25/71 28/67 34% improvement All studies 58% 0.42 [0.16-1.12] 25/300 28/142 58% improvement 3 N-acetylcysteine COVID-19 recovery results c19early.com/na Jan 16, 2022 Tau​2 = 0.73, I​2 = 95.5%, p = 0.082 1 CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huh 26% 0.74 [0.68-0.80] population-based cohort Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Prophylaxis 26% 0.74 [0.68-0.80] 26% improvement All studies 26% 0.74 [0.68-0.80] 26% improvement 1 N-acetylcysteine COVID-19 case result c19early.com/na Jan 16, 2022 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.33 Early treatment 80% 0.20 [0.01-4.85] 0/229 1/76 80% improvement de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 Improvement, RR [CI] Treatment Control Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Tau​2 = 0.00, I​2 = 0.0%, p = 0.00093 Late treatment 15% 0.85 [0.77-0.93] 21/138 23/135 15% improvement All studies 15% 0.85 [0.77-0.93] 21/367 24/211 15% improvement 4 N-acetylcysteine COVID-19 Randomized Controlled Trials c19early.com/na Jan 16, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.00084 Effect extraction pre-specified 1 CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ de Alencar (DB RCT) -3% 1.03 [0.41-2.27] 9/67 9/68 Improvement, RR [CI] Treatment Control Taher (DB RCT) 18% 0.82 [0.43-1.58] 12/47 14/45 Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Late treatment 11% 0.89 [0.53-1.50] 21/114 23/113 11% improvement All studies 11% 0.89 [0.53-1.50] 21/114 23/113 11% improvement 2 N-acetylcysteine COVID-19 RCT mortality results c19early.com/na Jan 16, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1 Improvement, RR [CI] Treatment Control Ignatova 20% 0.80 [0.64-1.00] hosp. time 56 (n) 55 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.043 Early treatment 21% 0.79 [0.63-0.99] 0/285 1/131 21% improvement de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 Improvement, RR [CI] Treatment Control Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Assimakopoulos 97% 0.03 [0.00-0.30] death 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] death 1/24 3/22 Tau​2 = 0.55, I​2 = 81.8%, p = 0.071 Late treatment 52% 0.48 [0.22-1.06] 24/204 38/197 52% improvement All studies 33% 0.67 [0.46-0.97] 24/489 39/328 33% improvement 7 N-acetylcysteine COVID-19 peer reviewed trials c19early.com/na Jan 16, 2022 Tau​2 = 0.11, I​2 = 73.8%, p = 0.035 Effect extraction pre-specified 1 CT: study uses combined treatment Favors N-acetylcysteine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Altay (DB RCT) 80% 0.20 [0.01-4.85] hosp. 0/229 1/76 CT​1 Improvement, RR [CI] Treatment Control Altay (DB RCT) 83% 0.17 [0.13-0.24] no recov. 229 (n) 75 (n) CT​1 Ignatova 20% 0.80 [0.64-1.00] hosp. time 56 (n) 55 (n) de Alencar (DB RCT) -3% 1.03 [0.41-2.27] death 9/67 9/68 de Alencar (DB RCT) -16% 1.16 [0.59-2.01] ventilation 16/67 14/68 de Alencar (DB RCT) 9% 0.91 [0.59-1.28] ICU 29/67 32/68 de Alencar (DB RCT) -12% 1.12 [0.77-1.65] ICU 67 (n) 68 (n) de Alencar (DB RCT) -10% 1.10 [0.37-3.23] hosp. time 67 (n) 68 (n) Gaynitdinova (RCT) 15% 0.85 [0.77-0.93] hosp. time 24 (n) 22 (n) Gaynitdinova (RCT) 51% 0.49 [0.32-0.75] Ct imp. 24 (n) 22 (n) Taher (DB RCT) 18% 0.82 [0.43-1.58] death 12/47 14/45 Taher (DB RCT) 14% 0.86 [0.53-1.40] ventilation 18/47 20/45 Taher (DB RCT) 20% 0.80 [0.44-1.47] ICU 47 (n) 45 (n) Taher (DB RCT) 33% 0.67 [0.31-1.45] hosp. time 47 (n) 45 (n) Taher (DB RCT) 15% 0.85 [0.60-1.22] no recov. 25/47 28/45 Assimakopoulos 97% 0.03 [0.00-0.30] death 2/42 12/40 Avdeev 69% 0.31 [0.03-2.72] death 1/24 3/22 Avdeev 77% 0.23 [0.03-1.90] ventilation 1/24 4/22 Avdeev 77% 0.23 [0.03-1.90] ICU 1/24 4/22 Avdeev 15% 0.85 [0.75-0.96] hosp. time 24 (n) 22 (n) Huh 26% 0.74 [0.68-0.80] cases population-based cohort N-acetylcysteine COVID-19 outcomes c19early.com/na Jan 16, 2022 1 CT: study uses combined treatment Favors N-acetylcysteine Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit